Oxford BioMedica: Notice of Preliminary Results
Results date: – 13 March 2015: Oxford, UK – 6 March 2015: Oxford BioMedica plc (LSE:OXB), (“Oxford Biomedica” or “the Company”) a leading gene and… Read More
Oxford BioMedica Announces Presentation at 27th Annual ROTH Conference
Oxford, UK – 5 March 2015: Oxford BioMedica plc (LSE:OXB), (“Oxford Biomedica” or “the Company”) a leading gene and cell therapy company, announces that Tim Watts, Chief Financial Officer, will present a company overview on 9 March 2015… Read More
Oxford BioMedica to Participate in Credit Suisse’s Global Healthcare One-on-One Conference
London, UK – 3 March 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene and cell therapy company, announces that John Dawson, Chief Executive Officer, and Tim Watts, Chief Financial Officer, will participate in… Read More
Chief Secretary to the Treasury visits Oxford BioMedica
Oxford, UK – 23 February 2015: Oxford BioMedica plc (LSE:OXB), (“Oxford Biomedica” or “the Company”) a leading gene and cell therapy company, today welcomed the Rt Hon Danny Alexander, Chief Secretary to the Treasury, to its laboratories on the Oxford… Read More
John Dawson, Chief Executive Officer, presented at Biotech Showcase™ 2015 Conference in San Francisco, on Monday, 12 January 2015
Biotech Showcase™ is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present… Read More
Oxford BioMedica Interim Management Statement
Oxford, UK – 3 November 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene and cell therapy company, today publishes its interim management statement for the period from 1 July to 31 October 2014. Read More
Oxford BioMedica Acquires Windrush Court Office and Laboratory Facilities
Oxford, UK – 13 October 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene and cell therapy company, announces that it has acquired the freehold of the Windrush Court office and laboratory facilities in… Read More
Oxford BioMedica announces new process development and manufacturing collaboration which includes LentiVector® licence agreement
Oxford, UK – 10 October 2014: Oxford BioMedica plc (LSE:OXB), (“Oxford Biomedica” or “the Group”) a leading gene and cell therapy company, announces today that it has signed further contracts with Novartis which build on the collaboration with… Read More
INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2014
Oxford, UK – 28 August 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a world-leading gene and cell therapy company, today announces its unaudited interim results for the six months ended 30 June 2014. Read More
Oxford BioMedica plc Directorate change
— Dr Paul Blake to take Executive Role as Chief Development Officer — Oxford, UK – 15 August 2014: Oxford BioMedica plc (LSE:OXB), (“Oxford Biomedica”… Read More
Oxford BioMedica to participate at the Piper Jaffray GenomeRx Symposium in New York on 23 June 2014
Oxford, UK – 23 June 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, today announces that it will attend Piper Jaffray’s GenomeRx Symposium on Monday, June 23, 2014 at The Yale… Read More
Loan Repayment in Full
Oxford, UK – 18 June 2014: Oxford BioMedica (“the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, announces that the Company has repaid in full the amount drawn down from the £5 million secured loan facility agreement, agreed on… Read More